secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003872
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track to CABA-201 for dermatomyositis and systemic sclerosis; cash $241M
--------------------------------------------------------------------------------

- FDA Fast Track Designations for CABA-201 in dermatomyositis (improve disease activity) and systemic sclerosis (improve organ dysfunction).
- Unaudited cash, cash equivalents and short-term investments of $241M as of Dec 31, 2023; cash runway into first half of 2026.
- Raised ~$94.1M in Q4 2023 via ATM program at avg $19.76/share (4.76M shares).
- Anticipates initial Phase 1/2 data for SLE and myositis in H1 2024; for SSc and gMG in H2 2024.
- Plans to file INDs for CABA-201 in additional autoimmune indications in 2024; combined US prevalence >1M patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524003872/0001193125-24-003872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524003872/d265299d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer